Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

 View HTML
0001950047-24-002762.pdf
0001950047-24-002762.rtf
0001950047-24-002762.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-009169.pdf
0001415889-24-009169.rtf
0001415889-24-009169.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-009009.pdf
0001415889-24-009009.rtf
0001415889-24-009009.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-008568.pdf
0001415889-24-008568.rtf
0001415889-24-008568.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-008593.pdf
0001415889-24-008593.rtf
0001415889-24-008593.xls
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

 View HTML
0001950047-24-002411.pdf
0001950047-24-002411.rtf
0001950047-24-002411.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-008124.pdf
0001415889-24-008124.rtf
0001415889-24-008124.xls
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

 View HTML
0001950047-24-002419.pdf
0001950047-24-002419.rtf
0001950047-24-002419.xls
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

 View HTML
0001972362-24-000411.pdf
0001972362-24-000411.rtf
0001972362-24-000411.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-007551.pdf
0001415889-24-007551.rtf
0001415889-24-007551.xls